The FDA is allowing C.R. Bard Inc. to change the primary endpoint to six months in the company's investigational device exemption (IDE) study for the Lutonix 014 drug-coated balloon (DCB) percutaneous transluminal angioplasty catheter. The modification comes as DCB technology stands out as a hot topic among interventional vascular and cardiology physicians this week at the annual VIVA meeting in Las Vegas. Read More
